Trial Parameters
Brief Summary
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
Eligibility Criteria
Inclusion Criteria: * Have objective, documented damage to the retina or optic nerve unlikely to improve OR * Have objective, documented damage to the retina or optic nerve that is progressive AND have less than or equal to 20/30 best corrected central visual acuity in one or both eyes AND/OR an abnormal visual field in one or both eyes. * Be at least 3 months post-surgical treatment intended to treat any ophthalmologic disease and stable. * If under current medical therapy ( pharmacologic treatment) for a retinal or optic nerve disease be considered stable on that treatment and unlikely to have visual function improvement ( for example, glaucoma with intraocular pressure stable on topical medications but visual field damage ). * Have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure. * Be over the age of 18 * Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care pr